Author + information
- Received September 19, 2019
- Revision received October 25, 2019
- Accepted December 12, 2019
- Published online May 4, 2020.
- Cristiano Spadaccio, MDa,∗,
- David Glineur, MD, PhDb,∗,
- Emanuele Barbato, MD, PhDc,
- Antonino Di Franco, MDd,
- Keith G. Oldroyd, MDe,
- Giuseppe Biondi-Zoccai, MD, MStatf,g,
- Filippo Crea, MDh,
- Stephen E. Fremes, MDi,
- Dominick J. Angiolillo, MD, PhDj and
- Mario Gaudino, MDd,∗ ()
- aDepartment of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom
- bDivision of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada
- cDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy
- dDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York
- eWest of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom
- fDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy
- gMediterranea Cardiocentro, Napoli, Italy
- hDepartment of Cardiovascular and Thoracic Sciences, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
- iSchulich Heart Centre, Division of Cardiac Surgery, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
- jDepartment of Cardiology, University of Florida College of Medicine, Jacksonville, Florida
- ↵∗Address for correspondence:
Dr. Mario Gaudino, Department of Cardio-Thoracic Surgery, Weill Cornell Medicine, 525 East 68th Street, New York, New York 10065.
Fractional flow reserve (FFR) provides an objective measurement of the severity of ischemia caused by coronary stenoses in downstream myocardial regions. Data from the interventional cardiology realm have suggested benefits of a FFR-guided percutaneous coronary intervention (PCI) strategy. Limited evidence is available on the use of FFR to guide coronary artery bypass grafting (CABG). The most recent data have shown that FFR might simplify CABG procedures and optimize patency of arterial grafts without any clear impact on clinical outcomes. The aim of this review was to summarize the available data on FFR-based CABG and discuss the rationale and potential consequences of a switch toward FFR-based surgical revascularization strategy.
↵∗ Drs. Spadaccio and Glineur contributed equally to this work.
Dr. Barbato has received speaker fees from Boston Scientific, Abbott Vascular, and GE. Dr. Oldroyd has served as a consultant for and received speaker fees from Abbott Vascular and Biosensors. Dr. Fremes has received grant support in part by the Bernard S Goldman Chair in Cardiovascular Surgery. Dr. Angiolillo has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has served as a consultant for CeloNova and St. Jude Medical; and has received institutional grant support from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- Received September 19, 2019.
- Revision received October 25, 2019.
- Accepted December 12, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.